Products Administration and submitted to the Japanese Ministry of Health, Labour and Welfare. According to InvestingPro analysis, GSK maintains a "GREAT" financial health score, positioning it ...

So, one of the milestones that I want to note right at the beginning of the article is that GSK announced that on January 28, 2025, regulatory authorities in China, Japan, and Europe accepted ...

Regulators in the EU, China, and Japan have started reviews of GSK's depemokimab, aiming to become the first drug for severe asthma that can be given just twice a year. The EMA and counterparts in ...